Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Prospective , Open Label, Phase 4 Trial of Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention With Drug-eluting Stent

Trial Profile

Randomized, Prospective , Open Label, Phase 4 Trial of Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention With Drug-eluting Stent

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cilostazol (Primary) ; Aspirin; Clopidogrel
  • Indications Myocardial infarction; Thrombosis
  • Focus Therapeutic Use
  • Acronyms SILOAM

Most Recent Events

  • 15 Nov 2021 Primary endpoint has (Major Adverse Cardiovascular and Cerebral Events) not been met according to the results presented at the American Heart Association Scientific Sessions 2021
  • 15 Nov 2021 Results presented at the American Heart Association Scientific Sessions 2021
  • 18 Feb 2020 Planned End Date changed from 28 Sep 2019 to 1 Mar 2022.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top